We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CUPID Disappoints Sanofi, Regeneron for Chronic Spontaneous Urticaria Drug
CUPID Disappoints Sanofi, Regeneron for Chronic Spontaneous Urticaria Drug
Sanofi and Regeneron have stopped their investigation of Dupixent (dupilumab) as a treatment for chronic spontaneous urticaria (CSU) in patients who don’t respond to Genentech’s Xolair (omalizumab).